Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Who’s Hired? Stada Appoints New UK Head

Amneal And Mayne Also Make Major New Appointments

Executive Summary

Summer’s end brings notable leadership reshuffles across four continents and five companies. Stada has appointed its head of mid-sized European markets as its UK lead while Gustavo Pesquin joins Amneal from Sanofi.

You may also be interested in...



Adcock Kept Cash Back For Two Major Deals, Prioritizes Partnerships

Adcock Ingram intends to continue seeking partnership deals with multinational firms, after failing to complete two significant acquisitions during its financial year ended 30 June 2022.

Stada Enjoys Robust First Half For Generics And Biosimilars

With generics and biosimilars sales continuing to flow in the first half of 2022, Stada reported healthy top- and bottom-line growth for the first six months of the year, including a 23% rise for its adjusted EBITDA.

Mayne Pharma CEO Steps Down Amid $475m Metrics Contract Services Sale

Significant change is brewing at Mayne Pharma, with the Australian firm announcing the proposed sale of its US-based CDMO business for nearly half-a-billion dollars. At the same time, long time CEO Scott Richards is heading for the exit door.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152155

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel